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Purpose of review
Here we review recent developments concerning the diagnosis, classification and
treatment of factor XIII (FXIII) deficiency and new findings related to the pathogenesis of
the disease.
Recent findings
Most recently, the International Society on Thrombosis and Haemostasis, Scientific and
Standardization Committee published a guideline for the diagnosis and classification of
FXIII deficiencies. Since 2009, three novel mutations causing severe bleeding diathesis
were discovered in the FXIII-A gene and one in the FXIII-B gene. A newly described
FXIII-A deficiency was of the extremely rare qualitative type II deficiency. The first well
established founder effect was reported for a causative FXIII-A mutation. More than a
quarter of all FXIII-A deficiencies are due to autoantibody, among them the first case of
deficiency caused by anti-FXIII-B autoantibody was reported in the last 2 years. The
safety and effectiveness of plasma FXIII concentrate for prophylaxis and treatment is
now well established. The new recombinant FXIII product is currently in phase III clinical
trial and the preliminary data are promising.
Summary
FXIII deficiency is considered the most underdiagnosed bleeding diathesis. The
recommended algorithm for its diagnosis and classification could improve the
diagnostic efficiency. The preferred choice for substitution therapy is FXIII concentrate
(plasma-derived or, in the future, recombinant).
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1065-6251Introduction
Blood coagulation factor XIII (FXIII) is a zymogen-type
coagulation factor, the precursor of a transglutaminase.
FXIII in the plasma (pFXIII) is a tetrameric complex
(FXIII-A2B2) of two potentially active A subunits (FXIII-
A; Mr 83 kDa) and two protective/carrier B subunits
(FXIII-B; Mr 80 kDa). Its cellular form (cFXIII),
a homodimer of FXIII-A (FXIII-A2), is present in the
cytoplasm of platelets, monocytes, and the monocyte-
derived macrophages including tissue macrophages (his-
tiocytes). pFXIII is synthesized in cells of bone marrow
origin, but the exact contribution of megakaryocytes
and monocytes/macrophages is not known. FXIII-B is
produced by the hepatocytes and the two types of
subunits form a complex in the plasma. In normal
conditions, all FXIII-A is present in the plasma as part
of the pFXIII complex, whereas FXIII-B is present in
excess. Approximately 50% of it circulates as a free, un-
complexed protein. FXIII-A, like other transglutami-
nases, consists of four well defined and sequentially
folded domains (beta sandwich, catalytic core, barrel 1opyright © Lippincott Williams & Wilkins. Unauth
1065-6251  2011 Wolters Kluwer Health | Lippincott Williams & Wilkinsand barrel 2 domains) and an N-terminal activation
peptide (FXIII-AP) of 37 amino acids, which is cleaved
off upon pFXIII activation. FXIII-B is a mosaic protein
that consists of 10 ‘sushi-domain’ repeats also known as
complement control protein modules, or short consensus
repeats. It prevents the rapid clearance of FXIII-A2
from the circulation and protects FXIII-A2 from a slow
spontaneous activation that would occur, in its absence,
at plasmatic Ca2þ concentration.
pFXIII is activated by the concerted action of thrombin
and Ca2þ in the final phase of the clotting cascade. Fibrin
serves as a powerful cofactor of the activation process;
it increases the rate of pFXIII activation by 80-fold and
the activation occurs on the surface of newly formed
fibrin. In this process, first thrombin cleaves the peptide
bond Arg37-Gly38 in FXIII-A and releases AP-FXIII
from the N terminus, and then, in the presence of
Ca2þ, the B subunits dissociate and FXIII-A2 assumes
an active configuration (FXIII-A2
). The Ca2þ-induced
structural changes result in a closed to open (extended)
structural transformation during which the active-siteorized reproduction of this article is prohibited.
DOI:10.1097/MOH.0b013e3283497e3e
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Key points
 Factor XIII (FXIII) deficiency has been considered
the most underdiagnosed rare hemorrhagic disorder.
 An algorithm is proposed for the diagnosis and classi-
fication of inherited and acquired FXIII deficiencies
according to the recommendations of theFactor XIII
and Fibrinogen Subcommittee of the International
Society on Thrombosis and Haemostasis, Scientific
and Standardization Committee.
 FXIII deficiency caused by an autoantibody against
a FXIII subunit is more frequent than originally
thought.
 The recommended substitution therapy for FXIII
deficiency is FXIII concentrate; virus-inactivated
plasma FXIII concentrate has been proven well
tolerated and efficient and recombinant FXIII
preparation is expected to be available in the near
future.cysteine, originally buried within the catalytic core
domain of FXIII-A, becomes unmasked and available
for reaction with its substrates.
Activated FXIII (FXIIIa), a transglutaminase, cross-links
peptide-bound glutamine and lysine residues through
isopeptide bonds; during the reaction, ammonia is
released. The main hemostatic functions of FXIIIa are
to cross-link fibrin chains and a2 plasmin inhibitor (a2PI)
to fibrin. The rapid formation of fibrin g-chain homo-
dimers and a2PI–fibrin a-chain heterodimers is followed
by the slower progressive cross-linking of fibrin a-chains
into high molecular weight polymers. By these bio-
chemical processes, FXIIIa mechanically stabilizes the
newly formed fibrin clot and protects it from shear
stresses and prompt degradation by the fibrinolytic
system. Most recent experiments suggest that FXIII also
supports the adhesion, spreading and fibrinogen binding
of platelets and clot retraction [1,2,3]. Further experi-
ments are required to prove whether a platelet function
defect also contributes to the severe bleeding diathesis of
FXIII-deficient patients. In addition to its hemostatic
functions, FXIII is also involved in wound healing and
angiogenesis and is essential for maintaining pregnancy.
For more details on the structure, activation and function
of FXIII, the most recent reviews should be consulted
[4,5].Clinical symptoms
FXIII deficiency can be congenital or acquired. Conge-
nital deficiency is a rare bleeding disorder (1 : 2 000 000)
transmitted as an autosomal recessive trait, with higher
frequency in countries where consanguineous marriages
are practised. Severe inherited FXIII deficiency is
characterized by life-long bleeding tendency, abnormal
wound healing and frequent spontaneous miscarriage
in affected women [6–13]. The bleeding tendency of
patients with inherited FXIII deficiency is severe in the
majority of cases. Delayed umbilical cord bleeding is
reported in about 80% of cases and can be considered
as diagnostic symptom of FXIII deficiency. The fact that
intracranial bleeding is reported in about 30% of cases
[14] makes primary prophylaxis mandatory in patients
affected with severe FXIII deficiency. Ecchymoses,
intramuscular and subcutaneous hematomas, oral cavity,
mouth and gingival bleeding and prolonged bleeding
following trauma are also characteristic symptoms [14].
The lack of large-scale clinical studies on heterozygous
FXIII-deficient patients does not allow drawing of
evidence-based conclusions on the prevalence of clinical
symptoms in this group of patients. Recently, Mahmoodi
et al. [15] reported clinical information on 350 hetero-
zygous individuals with inherited coagulation disorders,
and heterozygosity for XIII deficiency seemed to be
associated with prolonged or massive bleeding afterCopyright © Lippincott Williams & Wilkins. Unautminor traumas. However, these data need to be
confirmed in other cohorts of patients.
The uncertainty of most commonly used FXIII activity
assays in the low-activity range makes it difficult to obtain
accurate correlation between genotype, laboratory
phenotype and clinical severity. In the great majority
of patients with FXIII-A deficiency, FXIII activity is
lower than 5% [14]. Clinical symptoms are rather
unpredictable; in some patients, long period of only mild
symptoms might be followed by severe bleeding
complications [14]. To date, even though the involve-
ment of FXIII in hemostasis has been well characterized,
there are still some aspects of FXIII deficiency that need
to be clarified. Little information is available on the role
of FXIII in pregnancy, particularly in the process of
placentation, which could explain the high rate of mis-
carriages. It is also important to explore why wound-
healing disorder could be observed only in a fraction of
patients with severe FXIII deficiency.Classification of FXIII deficiencies
The former classification distinguishing between type I
(combined deficiency of FXIII-A and FXIII-B) and type
II (FXIII-A deficiency) deficiencies has been outdated
by the finding that patients assumed to have type I
combined deficiency are defective in the FXIII-B gene
[16] and that the lower level of FXIII-A is due to its
accelerated clearance from the circulation in the absence
of the protective FXIII-B. The combined defect of
FXIII-A and FXIII-B genes is highly unlikely; no such
case has been published in the literature. This classifi-
cation causes confusion; it should not be used any more.
The classification recommended by the International
Society on Thrombosis and Haemostasis, Scientific and
Standardization Committee (ISTH SSC), Factor XIIIhorized reproduction of this article is prohibited.
C368 Hemostasis and thrombosisand Fibrinogen Subcommittee has been published as
an official SSC communication [17] and is shown in
Table 1.
Inherited FXIII deficiencies are classified as FXIII-A
and FXIII-B deficiencies; subtypes I and II of FXIII-A
deficiency represent quantitative and qualitative defects,
respectively. The gene coding FXIII-A (F13A1) is
located on chromosome 6 at the 6p25.3–p24.3 position
and contains 15 exons producing a 3.9-kb mRNA,
whereas the FXIII-B gene (F13B) is located on chromo-
some 1 at the 1q31–32.1 position and comprises 12 exons
producing a 2-kb mRNA. FXIII deficiency is of auto-
somal recessive inheritance; patients with severe disease
are homozygotes or compound heterozygotes. Causative
mutations have been found in FXIII-A and FXIII-B
genes and are listed in different databases (www.
f13-database.de, www.med.unc.edu/isth/mutations-data-
bases and www.hgmd.cf.ac.uk). More than 70 mutations
within the FXIII-A gene and four mutations in the FXIII-
B gene were reported until 2009. The location of these
mutations is summarized in another study [14]. Since
then several interesting reports have been published on
inherited FXIII deficiency. Morange et al. [18] reported
a novel homozygous four bases insertion in exon 14
(c.2116insAAGA) introducing a frameshift that after
seven altered amino acids results in a stop codon and
a protein with a truncated second b-barrel domain
(p.Pro675TyrfsX7). Interestingly, the deficiency is of
the extremely rare type II variant. The mutant protein
lost its activity, but the plasma FXIII antigen level was at
the lower limit of the reference interval. This finding
suggests that the C-terminal part of b-barrel 2 is essential
for the expression of FXIII activity. Ivaskevicius et al.
[19] also described a novel homozygous mutation result-
ing in a stop codon in the same area of b-barrel 2
(c.1994G>A; p.Trp664X). Unfortunately, in this case,
FXIII antigen level was not reported and the subtype
of deficiency could not be established. Another novelopyright © Lippincott Williams & Wilkins. Unauth
Table 1 Laboratory diagnosis/classification of factor XIII deficienc
Plasma
Activity A2B2
Inherited deficiency
FXIII-A deficiency
Type I ### ###
Type II ### #-n
FXIII-B deficiency ## ###
Autoantibody against FXIII
Anti-FXIII-A antibody
Neutralizing ### #-n
Nonneutralizing ### ###
Anti-FXIII-B antibody
Nonneutralizing ### ###
Other acquired deficiency # #
###, highly decreased activity/concentration usually below 30%; ##, con
decreased activity usually in the range of 20–70%; n, normal; na, nonapplmutation in b-barrel 2 (p.Arg703Trp) occurred in
compound heterozygous arrangement. Interestingly, its
appearance seems to constitute a de-novo event, the first
one reported in the FXIII-A gene [20]. It was shown
in two parallel publications that a small insertion
(c.869insC) is the dominant mutation in Tunisian
FXIII-A-deficient patients, which is due to an ancient
founder effect [21,22]. In addition to the five previously
described mutations in the FXIII-B gene that led to
homozygous or compound heterozygous FXIII-B defi-
ciency, a new homozygous case with duplication in exon
7 (c.1155_1158dupACTT) was reported [23]. The
mutation resulted in a protein lacking the last five sushi
domains.
Acquired FXIII deficiencies consist of two main groups:
the autoantibodies against a FXIII subunit and the other
moderate FXIII deficiencies caused by decreased
synthesis of a FXIII subunit due to impaired bone
marrow function or liver disease, by consumption of
FXIII or by dilution coagulopathy. Discussion of the
latter moderate deficiencies is beyond the scope of this
review. Up to 2009, 36 cases of FXIII deficiencies due to
an anti-FXIII-A autoantibody were reported in the
literature, whereas in the last 2 years, 14 additional cases
were reported [24,25,26,27], which suggests improved
laboratory diagnostics and/or clinical awareness. In
supplemented patients with inherited FXIII deficiency,
the development of an antibody against FXIII is
extremely rare. In about one third of the patients, the
anti-FXIII autoantibody develops in patients with auto-
immune disease, most commonly with systemic lupus
erythematosus. However, in a significant portion of
the patients, the autoantibody is idiopathic and develops
in elderly individuals. Autoantibodies against FXIII-A
could be of neutralizing or nonneutralizing type. The
former interferes with the activity of FXIIIa or with
FXIII activation, whereas the latter type of autoanti-
body forms an immune complex with the respectiveorized reproduction of this article is prohibited.
ies
FXIII Platelet FXIII
A2 B Activity A2
### >30% ### ###
#-n >30% ### #-n
## ### n n
#-n >30% n n
### >30% n n
### ### n n
# #-n na na
siderably decreased activity/concentration usually 5–10%; #, slightly
icable. Reproduced with permission from [17].
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rapidly cleared by the reticulo-endothelial system.
Earlier publications mostly report neutralizing anti-
FXIII-A autoantibodies; this, however, could be due to
the diagnostic difficulties in detecting nonneutralizing
autoantibodies. In a most recent Japanese study, 11
patientswithnonneutralizing anti-FXIII-A autoantibodies
were reported as opposed to five with neutralizing anti-
bodies [24]. An autoantibody against FXIII-B was first
reported in 2009 [28]. It formed a complex with FXIII-B
and FXIII-A2B2 and highly accelerated their clearance
from the circulation causing life-threatening bleeding
complications. Another less characterized case was repor-
ted most recently [24].Laboratory diagnosis of FXIII deficiencies
Figure 1 presents an algorithm for the classification
of FXIII deficiencies and Table 1 summarizes the results
expected in the different subtypes. The algorithm for
the diagnosis and classification of FXIII deficienciesCopyright © Lippincott Williams & Wilkins. Unaut
Figure 1 Algorithm for the diagnosis and classification of factor X
Plasma FXII
FXIII-A defic
FXIII activity
measurement
in mixing study
Additional tests : platelet FXIII-A activity
cross-linkings by SDS PAGE analysis o
plasma, molecular genetic tests to 
FXIII-A deficiency type II
or
neutralizing antibody
against FXIII-A
FXIIIA2B2 an
decrease
Normal
If autoantibody
is suspected
For details on the mixing study and binding assay see supplementary matecrystallized out in the last years [14,17] and reagent
kits required for full classification are now available
commercially (see supplementary material in [17]).
Still, FXIII deficiency remained the most under-
diagnosed coagulopathy, partly due to the practise of
using clot solubility in concentrated urea (alternatively
in diluted monochloroacetic acid or acetic acid) solution
as the screening test for FXIII deficiency. This test is now
obsolete, is poorly standardized and detects only very
severe FXIII deficiency with FXIII activity below 1–5%.
The screening test, which establishes the diagnosis of
FXIII deficiency, should be a FXIII activity assay. FXIII
activity assays are based on two principles: they measure
the ammonia released during the transglutaminase reac-
tion by the NAD(P)H-dependent glutamate dehydro-
genase reaction spectrophotometrically at 340 nm or
measure the amount of a small molecular weight labeled
amine substrate covalently linked to a protein. In the
latter case, the free and bound radiolabeled, fluorescent
or biotinylated amine should be separated. A detailedhorized reproduction of this article is prohibited.
III deficiencies
I activity
iency
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rial in [17].
C370 Hemostasis and thrombosisreview and comparison of the two types of methods is
given in [14,17]. Briefly, the ammonia release methods
are quick kinetic tests, are easy to perform and can be
automated [29], but their sensitivity in the low-activity
range (below 5% FXIII activity) should be improved.
Most recently, earlier recommendation [30] on the
deduction of plasma blank measured in the presence
of a FXIIIa inhibitor has been confirmed [29]. Without
plasma blank deduction, due to FXIIIa-independent
NAD(P)H consumption, the ammonia release assays
overestimate FXIII activity in the low-activity range.
The amine incorporation tests are more sensitive, but
they are laborious, nonkinetic tests and cannot be applied
to automatic analyzers. The diagnostic tools used for the
classification of FXIII deficiencies include FXIII-A2B2,
FXIII-A and FXIII-B antigen determinations from the
plasma, FXIII activity and FXIII-A antigen measure-
ment from the platelet lysate produced by a nonionic
detergent. Study of fibrin cross-linking by SDS PAGE
analysis of washed plasma clot is a useful addition and
genetic analysis confirms the diagnosis.
For the detection and quantification of a neutralizing anti-
FXIII-A antibody, a mixing study according to an adap-
tation of the Nijmegenmodification of the Bethesda assay
is recommended (see supplementary material in [17]).
Demonstration of thebinding of thepatient’s IgG (IgM) to
isolatedFXIII subunits andFXIII complex in anELISAor
dot blot arrangement is required to diagnose the presence
of a nonneutralizing anti-FXIII autoantibody [24,28].
To verify the accelerated clearance of FXIII from the
circulation, the decrease of FXIII activity/antigen is to be
followed by serial measurements following supplement-opyright © Lippincott Williams & Wilkins. Unauth
Figure 2 The detection of anti-FXIII-B autoantibody
Patient IgG (g/l)
OD
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(a) The binding of the patient’s biotinylated IgG to purified FXIII-A2, FXIII-B an
avidin-biotinylated peroxidase complex. (b) Plasma FXIII activity at various inte
CSL Behring, Marburg, Germany) to the patient. The horizontal broken line re
when half of the added FXIII activity was eliminated from the circulation. The
normal half-life of approximately 12 days. Reproduced with permission of thation [27,28]. An example for the diagnosis of non-
neutralizing autoantibody is shown in Fig. 2.Replacement therapy (prophylaxis, on
demand treatment)
Primary prophylaxis (10/20U/kg FXIII every 4–6 weeks)
is recommended for patients with severe FXIII defi-
ciency in order to prevent spontaneous severe bleedings,
abnormal wound healing and recurrent miscarriages
in women. Although fresh frozen plasma (FFP) and
cryoprecipitate contain FXIII, highly purified and heat-
treated FXIII concentrate is preferred for long-term
prophylaxis [31]. The half-life of FXIII is the longest
among coagulation factors (11–14 days). It has been
suggested that a level of 5% is sufficient to prevent
spontaneous bleeding [32]. According to more recent
analyses, a level higher than 10% is needed to reduce
the occurrence of bleedings significantly, but still leaving
10% of patients with cutaneous bleeding (EN-RBD;
http://www.rbdd.eu). Before the introduction of FXIII
concentrate, cryoprecipitate and FFP were the choice of
FXIII supplementation. Now, fibrogammin P, a purified
pasteurized concentrate, is available for prophylaxis in
a recommended dosage of 10–20U/kg once every 4–
6 weeks. In major surgery, 20–30U/kg per day should be
administered to achieve a level above 5% until healing is
complete; in minor surgery, a dose of 10–20U/kg per day
for 2–3 days is recommended, whereas in spontaneous
bleeding, the treatment varies from 10–20 to 20–30U/kg
per day, depending on the severity of bleeding,
until bleeding stops [14,32–35]. Replacement therapy
throughout pregnancy is essential for the prevention oforized reproduction of this article is prohibited.
FXIII
activity
(%)
Hours after 3750 U
Fibrogammin
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40
20
0
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(b)
d FXIII-A2B2 coated to a microtiter plate. The reaction was developed by
rvals following the administration of 3750U plasma FXIII (Fibrogammin-P,
presents half-maximal FXIII activity; the vertical dotted line shows the time
half-life of FXIII in the patient’s circulation was 17h, as opposed to the
e American Society of Hematology [27].
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women. Limited data on prophylaxis during pregnancy
are available; a plasma FXIII level above 10% seems to be
sufficient for successful pregnancy. Asahina et al. [9] have
reported that 250 IU per week were sufficient to maintain
this level in the early period of gestation, and 500 IU per
week is recommended after the 23rd week of gestation.
The same authors propose that plasma FXIII level should
be higher than 30% during labor and a booster dose of
1000 IU is recommended before labor to prevent severe
obstetrical hemorrhagic complication. The use of
treatments raises the problem of development of auto-
antibodies; however, in patients treated with FFP, cryo-
precipitate or plasma-derived FXIII concentrate, the
incidence of inhibitor development was extremely low
[36]. To date, no severe bleedings and no serious adverse
events have been reported in patients treated with
fibrogammin P [34,37].
A new human recombinant FXIII-A2 (rFXIII-A2)
(Novo Nordisk, Bagsvaerd, Denmark) product has been
developed for FXIII substitution therapy. Safety and
pharmacokinetics of a single administration of rFXIII
was investigated in a phase I escalating-dose study
[38]. No serious adverse event and no development of
specific autoantibodies were observed during the study.
rFXIII formed a complex with endogenous FXIII-B and
the half-life of administered rFXIII was similar to that of
FXIII tetramer. It was effective in restoring clot strength
and resistance to fibrinolysis. rFXIII is currently in phase
III clinical trials. At the 52nd American Society of Hema-
tology Annual Meeting, Inbal et al. [39] reported the
experience with 41 FXIII-deficient patients treated with
rFXIII-A2. During the treatment, five bleeding episodes
were observed and all five occurred after trauma. Four
patients developed transient, nonneutralizing, low-titer
anti-rFXIII antibodies. These antibodies appeared to
be clinically insignificant and no patients developed
anaphylactic or allergic reactions. However, the import-
ance of such nonneutralizing anti-FXIII antibodies still
needs to be investigated.
The treatment of FXIII deficiency caused by anti-FXIII
autoantibody might be extremely difficult and in most
cases requires the use of a whole armory of therapeutic
tools. Apart from substitution with FXIII concentrate,
these include sometimes aggressive, immunosupressive
therapy, plasmapheresis, the administration of IgG
preparation, anti-CD20 or recombinant FVIIa [24,25,
26,28]. In one patient, spontaneous regression was also
described [27].Conclusion
FXIII deficiency has been considered the most under-
diagnosed rare hemorrhagic disorder. The most recentCopyright © Lippincott Williams & Wilkins. UnautISTH SSC recommendation for its diagnosis and
classification aims to improve the diagnostic efficiency.
Recent studies explored novel mutations in the FXIII-A
and FXIII-B genes and the first well established founder
effect was reported. Recent reports suggest that FXIII
deficiency caused by an autoantibody against a FXIII
subunit is more frequent than originally thought. The
preferred choice for substitution therapy is FXIII concen-
trate. The plasma-derived concentrate is well tolerated
and efficient and a recombinant product is expected to be
available in the near future.
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